GLP-1 Users May Face Optic Nerve Damage Risk in First Year
The use of GLP-1 receptor agonists, and particularly liraglutide, was associated with an increased risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) during the first year of treatment, with the risk being most pronounced in individuals without type 2 diabetes (T2D) or obesity.
METHODOLOGY:
Researchers conducted a case-control study to examine the association between the use of GLP-1 agents and development of NAION.
They analyzed data from 65,612 patients with NAION who had obesity, T2D, or neither and matched them with 641,751 control participants by age, exact year of insurance enrollment, and history of T2D or obesity.
Exposure to GLP-1 was defined by use (ever or never) and duration of continuous use (1, 2, or ≥ 3 years), according to dispensed prescriptions for dulaglutide, liraglutide, semaglutide, or exenatide.
TAKEAWAY:
The use of any GLP-1 agent was associated with 19% higher odds of developing NAION in the first year (odds ratio [OR], 1.19; 95% CI, 1.02-1.39), with the use of liraglutide tied to an even greater risk for the condition (OR, 1.53; 95% CI, 1.18-1.98).
The association between exposure to a GLP-1 drug and development of NAION was stronger in people without T2D or obesity using any of these medications (OR, 2.03; 95% CI, 1.07-3.85) and especially liraglutide (OR, 2.32; 95% CI, 1.04-5.20).
IN PRACTICE:
'The aforementioned associations for extended semaglutide use and liraglutide use among individuals without obesity or T2D are interesting, given these medications are increasingly being used for weight management,' the researchers reported. 'Future research including reasons for GLP-1RA [receptor agonists] use among this group and larger sample sizes could clarify whether these associations exist in this population or result from obesity or T2D diagnosis exposure misclassification or low exposure prevalence in this study,' they added.
SOURCE:
This study was led by Pallavi Nagdeve, MPH, and Russell Griffin, PhD, of the University of Alabama in Birmingham, Alabama. It was published online on July 24, 2025, in JAMA Ophthalmology.
LIMITATIONS:
The use of standard diagnostic codes may have led to misclassification of other optic neuropathy cases as NAION. Information available from the database used in this study was limited, and the reported associations may have been biased by unknown factors.
DISCLOSURES:
This study did not report any source of funding. The authors reported having no relevant financial conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Targeting energy expenditure: the next wave for obesity drugs
In the wake of their seismic ascension over the lucrative weight loss market, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are facing scrutiny over side effects and post-treatment weight regain. As next generation weight loss alternatives emerge, one particular type—mitochondria-targeting drugs— are being positioned as safer and more sustainable options. In a global obesity market estimated by GlobalData to reach $173.5bn by 2031, GLP-1RAs retain the lion's share. In 2031, Novo Nordisk is projected to bring in $22.8bn and $21.7bn that year from sales of its semaglutide formulations Ozempic and Wegovy, respectively. Meanwhile, Eli Lilly is expected to outpace the Danish giant with its tirzepatide formulation projected to earn $36bn as Mounjaro and $28bn as Zepbound. Alongside their efficacy, side effects including nausea and loss of muscle or bone mass, have become increasingly apparent. This is a significant problem for GLP-1RAs, according to Dr. Antonio Vidal-Puig, professor of molecular nutrition and metabolism at Cambridge University, UK. As GLP-1RAs decrease patient appetite, they also downregulate energy expenditure by lowering the resting metabolic rate. Vidal-Puig says this is a key factor behind the weight regain often experienced by patients after stopping GLP-1RAs. Mitochondrial modulators propose a solution. Rather than limiting appetite, these drugs target the cell's mitochondria to increase the resting rate of metabolism and raise energy expenditure to encourage weight loss. Developers say preclinical and early clinical data show these approaches offer weight loss comparable to GLP-1RAs, but with less lean mass loss and more sustainable results. However, whether mitochondrial modulators can be controlled enough to remain safe at efficacious levels, or whether their impact can targeted away from certain mitochondria such as those in cardiac tissue, essential for heart function, is key to whether they can become viable weight loss therapies says Olivier Boss, CEO of Energesis Pharmaceuticals, based in Cambridge, Massachusetts. Energesis's therapeutic approach does not modulate mitochondria directly but rather increases brown fat to enhance thermogenesis. Since they take a distinct approach from GLP-1RAs, these drugs could be complementary. By combining GLP-1RAs with mitochondrial modulators, Vidal-Puig envisions a maintenance of a healthy metabolic rate while minimising the side effects of either therapy class through lowered doses. Boss adds that the next generation of obesity treatments must include agents that increase resting metabolic rates. Mitochondrial modulators encompass a number of approaches taken by biotechs to target the mitochondria and energy expenditure. Here are some of the key ones: Mitochondrial uncouplers Mitochondria create a gradient by pumping protons into the intermembrane space. The gradient allows protons to re-enter the inner mitochondria through ATP-synthase channels, which generates ATP. Uncouplers, or protonophores, open channels across the mitochondrial membrane, forcing the mitochondria to expend energy, maintaining a proton gradient without commensurate ATP production. Foremost in the class is HU-6, developed by Charlottesville, Virginia-based Rivus Pharmaceuticals. In a Phase IIa trial (NCT05284617) of 66 participants with obesity-related heart failure with preserved ejection fraction (HFpEF), patients lost a mean 6.8lbs in weight compared to 0.5lbs with placebo (p=0.0026), reducing body fat by a mean 4.8%, as per a 12 March 2025 press release. Notably, there were no significant changes to lean or skeletal muscle mass with HU-6 treatment. Palo Alto, California-based OrsoBio is also studying a mitochondria uncoupler, TLC-6740, in a Phase I study (NCT05822544). Preclinical data with another of the company's uncouplers, TLC-3595, showed that lowered blood sugar in mice by as much as 40%, on par with semaglutide, as per a poster at the American Diabetes Association 2024 meeting. Creatine-dependent thermogenesis Eolo Pharma is developing a small molecule called MVD-1, which activates creatine-dependent thermogenesis to raise energy expenditure by enhancing mitochondrial respiration. As per results published in Nature, a 3% weight loss over two weeks with MVD-1 in a Phase I trial (ACTRN12622001519741) was observed, which the study's authors said was similar to the efficacy of semaglutide. No serious adverse events were reported. Sunchales, Argentina-based Eolo's CEO María Pía Garat emphasises MVD-1 does not have the same impact on patients' lifestyles as GLP-1RAs since it does not suppress appetite, potentially instilling longer-term weight management. With a Phase II trial planned to begin by the end of 2025, Garat says Eolo ultimately hopes to target patients dissatisfied with the side effects of GLP-1RAs. Pyruvate carrier modulators In preclinical development is azemiglitazone, a pyruvate carrier modulator being developed by Grand Rapids, Michigan-based Cirius Therapeutics. It targets the mitochondrial target of thiazolidinedione (mTOT) protein to inhibit the import of the metabolic product pyruvate into the mitochondria. This increases insulin sensitivity, encourages production of mitochondria, and favours the metabolism of fats. Results from a study in mice presented at the 2024 European Association for the Study of the Liver (EASL) Congress showed azemiglitazone with liraglutide led to significant preservation of lean body mass over liraglutide alone. Liraglutide is sold by Novo Nordisk as Saxenda. The therapy also increased brown adipose tissue, key to weight loss according to Boss. He notes brown adipose cells have a greater number of mitochondria than white cells, meaning this tissue is disproportionally responsible for energy expenditure. Sulfide donors Oxford, UK-based MitoRx Therapeutics is taking another approach involving the mitochondria. Myo-4 restores dysfunctional sulfide signaling in mitochondria to enhance metabolism, an approach stemming from the work of cofounder and CSO Matthew Whiteman, PhD, who found that fat loss correlates with systemic levels of sulfur-containing amino acids in patients. As per data presented at the 2025 European Conference on Obesity in May, Myo-4 normalised blood sugar levels in mice while reducing the loss of muscle and bone mass in comparison to semaglutide. 'We've got immense advantages over a GLP-1RA,' says Jon Rees, MitoRX CEO. The company plans to begin clinical study in 2027. New approaches raise fresh concerns Boss believes the next generation of obesity treatments must include agents like these that increase resting metabolic rates. His own company is developing therapeutics to enhance energy expenditure for weight loss by increasing patients' brown fat mass. But he warns that in their effort to overcome the shortcomings of GLP-1RAs, mitochondrial modulators introduce their own risks. According to Vidal-Puig, strategies like uncoupling may be effective in brown fat cells, but uncouplers need to be targeted to these tissues and away from other organs like the heart, liver, and kidneys where mitochondria support vital functions. Unless this is achieved, he suspects the window between minimum effective doses and maximum tolerated ones could prove too narrow. Boss points out that as far back as 1938, the uncoupler dinitrophenol saw its US Food and Drug Administration (FDA) approval withdrawn over safety concerns. Beyond uncouplers, he says target selectivity is a key issue for other mechanisms such as creatine-dependent thermogenesis. Though effective in brown fat cells, he notes these are sparse among obese patients with greater numbers of white fat cells. A synergistic solution In terms of where these drugs might fit in the current landscape, Boss says 'We're not trying to replace GLP1-RAs, but to complement them.' Garat says Eolo is also considering a similar approach. In both cases, developers have found encouraging results in combination with GLP-1RAs. Vidal-Puig suggests mitochondrial modulators could bolster GLP-1RAs by maintaining patients' rate of energy expenditure to better sustain weight loss and retain bone and muscle. Combined treatments would likely also lower the doses of GLP-1RAs needed, which Boss believes could be key in limiting their associated side effects such as nausea. In contrast, Rees envisions Myo-4 as a monotherapy. 'In 10 years' time, it won't be acceptable to people who are living with obesity to risk loss of muscle mass and function', he states. 'This is the first flush of weight loss medicines. They've created a huge market and now it's time for the next generation of molecules to come forward.' "Targeting energy expenditure: the next wave for obesity drugs" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
2 hours ago
- The Hill
Weight loss drugs may boost testosterone in men, study finds
GLP-1 weight loss medications like Ozempic and Wegovy could increase testosterone levels and help prevent erectile dysfunction in men, according to a new study. While more data is needed, researchers from St. Louis University Hospital saw significant increases in testosterone levels for men with obesity or Type 2 diabetes while taking GLP-1 medication. Men who experience obesity or have Type 2 diabetes often have lower levels of testosterone, which can impact sexual function, muscle mass and bone density. In the study, the testosterone levels of 110 adult men with obesity or Type 2 diabetes, who were taking GLP-1 medications and not taking testosterone therapies, were analyzed before and throughout 18 months of treatment. The average age in the study was 54. The study showed that in addition to weight loss, 'the proportion of men with normal levels of both total and free testosterone rose from 53% to 77%,' according to the Endocrine Society. 'Our study is among the first to provide compelling evidence that low testosterone can be reversed with the use of commonly prescribed anti-obesity medications,' said Dr. Shellsea Portillo Canales, an endocrinologist at St. Louis University Hospital. The study's findings also came with certain limitations. The study was retrospective, meaning researchers analyzed electronic health records rather than conducting a clinical trial. In addition, the testosterone levels of men included in the study were not measured after they stopped taking the GLP-1 medications. 'If weight is regained, testosterone levels could potentially drop again,' Portillo told NBC News. GLP-1 medications have exploded in popularity due to their efficacy in controlling blood glucose and weight management, according to UChicago Medicine. The results of the study were presented at ENDO 2025, the Endocrine Society's yearly meeting in San Francisco.
Yahoo
3 hours ago
- Yahoo
Crinetics Pharmaceuticals, Inc. (CRNX)' Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data
We recently compiled a list of Crinetics Pharmaceuticals, Inc. stands fifth on our list. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands fifth on our list among the best future growth stocks to buy now. It is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies for rare endocrine diseases and tumors. Its lead candidate, PALSONIFY (paltusotine), is an investigational once-daily oral somatostatin receptor type 2 (SST2) agonist being developed for acromegaly. At the July 2025 ENDO Annual Meeting, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) presented long-term data from the open-label extensions of its PATHFNDR-1 and PATHFNDR-2 Phase 3 trials, showing that PALSONIFY maintained durable IGF-1 control, reduced symptom burden, and had a consistent safety profile. These findings strengthen its case as a next-generation oral alternative to current injectable therapies, which are the standard of care for acromegaly. The company is now approaching a major inflection point, with a PDUFA date set for late 2025, potentially making PALSONIFY the first oral treatment approved for acromegaly. This would represent a significant shift in disease management and convenience for patients. A scientist in a laboratory looking into a microscope, researching advances in biopharmaceuticals for central nervous system disorders. Beyond PALSONIFY, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is advancing other pipeline programs, including Atumelnant, aimed at treating congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, as well as several early-stage endocrine disorder therapies. The corporation also expanded its workforce in July 2025, granting equity awards to 46 new employees to support future growth. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
